Company intelligence
DLRC Regulatory Consultancy
Supporting the life science developer’s journey to success for the benefit of patients | Certified B Corporation ™
About DLRC Regulatory Consultancy
Bringing your product to market is complex; DLRC helps simplify the journey. Operating from our UK, Germany and US offices, we partner globally with life science developers of all sizes, from early-stage start-ups and SMEs to top five global pharmaceutical companies. Our senior-led teams develop and deliver phase-appropriate strategies across regulatory affairs, HTA and market access, supporting products from non-clinical development through to post-approval and lifecycle management. We combine deep regulatory expertise with practical HTA and market access insight, helping companies plan evidence generation, engage confidently with regulators and payers and make informed decisions that support timely patient access. Our consultants are experienced specialists in non-clinical, CMC, clinical development, MedTech, HTA and market access, with backgrounds in industry, health authorities, and assessment agencies. Our commitment to quality and regulatory excellence has been recognised through multiple industry and business awards and accreditations, including the Queen’s and King’s Awards for Enterprise in International Trade, TOPRA Awards for Regulatory Excellence, ISO 9001 accreditation, Investors in People Silver and Cyber Essentials. We are a Certified B Corporation™, reflecting our commitment to high standards of social, environmental and governance performance. DLRC also has Science Based Targets initiative (SBTi) validated targets, confirming that our climate goals are aligned with recognised, science‑based emissions reduction pathways. We work with Planet Mark to calculate and monitor our carbon emissions, supporting our ongoing environmental commitments. Speak to us to find out how our integrated regulatory, HTA and market access expertise can support your organisation and help bring innovative products to patients sooner.
Verified activity
Signals from DLRC Regulatory Consultancy
6 published signals
Presence & Recognition
DLRC Regulatory Consultancy Business Development Lead Ankita Jain is attending NLS Days 2026 at the British Embassy in Sweden.
Reported by DLRC Regulatory Consultancy
Research & Knowledge
DLRC Regulatory Consultancy published an article exploring the implications of the proposed EU Pharmaceutical Reform for industry and how ePI may transform medicines information creation, management, and access.
Reported by DLRC Regulatory Consultancy
People
DLRC Regulatory Consultancy welcomed Krishna Patel as a Senior Regulatory Associate joining the team.
Reported by DLRC Regulatory Consultancy
Legal & Regulatory
DLRC Regulatory Consultancy received a newly published position paper from the MHRA regarding microbiome-based medicinal products and their development and licensing in the UK.
Reported by DLRC Regulatory Consultancy
Presence & Recognition
DLRC Regulatory Consultancy Business Development Lead Ankita Jain will attend NLS Days 2026 as part of the event.
Reported by DLRC Regulatory Consultancy
Presence & Recognition
DLRC Regulatory Consultancy Global Business Development Lead Stuart Hunter will attend BIOSPAIN in Bilbao, Spain, this year.
Reported by DLRC Regulatory Consultancy